61 research outputs found
Sensitivity of normal and malignant human lymphocytes to 5-aminolevulinic acid-mediated photodynamic damage
Aim: To compare the sensitivity of normal and malignant human lymphocytes to 5-aminolevulinic acid (ALA) β mediated photodynamic damage. Methods: Blood lymphocytes isolated by Ficoll-sodium metrizoate density gradient from healthy donors (6) and hematologic patients (20) with different forms of lympholeukemia, and also transformed lymphocytes of human B-cell (Raji, Namalwa) and T-cell (MT-4, HUT-78) lines were inestigated. Diagnoses of chronic lymphoproliferative disorders were made on the grounds of morphological, cytochemical and immunocytochemical studies of peripheral blood and bone marrow cells, with immunophenotype determination by monoclonal antibodies to differentiation antigens of T, B lymphocytes and NK cells and immunocytochemical ABC-AP method. Cells of leukemic B- and T-cell lines were cultured in standard RPMI-1640 medium. For photodynamic treatment, the cells were incubated with ALA and then irradiated by a helium-neon laser (wavelength of 633 nm). The number of dead cells was determined in 20 h with trypan blue dye exclusion test. Results: The striking difference in responsiveness to ALA-mediated photodynamic treatment (ALA-PDT) between normal lymphocytes and cells isolated from lymphatic leukemia patients was established. A bulk of leukemic cells (mean for 10 patients with B-CLL β 62.06 Β± 4.03%) were destroyed under the lowest ALA-PDT doses tested: 1 mM ALA, irradiation dose of 25 J/cm2. However, it was virtually impossible to attain any appreciable damage of lymphocytes from healthy donors even with the highest treatment doses (5 mM ALA, 150 J/cm2). High sensitivity to ALA-PDT of malignant lymphocytes was confirmed in experiments with human T- and B-cell leukemic cell lines, and in these experiments, an anomalous reaction to the treatment of Raji cells was also detected. The mechanisms of the difference between normal and malignant lymphocytes are discussed in terms of altered heme-synthesis processes in malignant cells. Conclusions: 1) It is shown for the first time that blood lymphocytes from lymphatic leukemia patients are highly sensitive to the damage with ALA-PDT while lymphocytes of normal donors are practically not damaged. 2) Transformed lymphocytes of human T-cell lines are more sensitive than lymphocytes of B-cell lines. 3) Lymphocytes of the Raji line display anomalous dose-effect dependence with ALA-PDT. 4) It is proposed to evaluate the drastic difference in ALA-PDT responsiveness of normal and malignant lymphocytes as a possible simple and low-traumatic test for B-CLL screening among the elderly people.Π¦Π΅Π»Ρ: ΠΈΠ·ΡΡΠΈΡΡ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΊ ΡΠΎΡΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΌΡ Π²ΠΎΠ·Π΄Π΅ΠΉΡΡΠ²ΠΈΡ, ΠΎΠΏΠΎΡΡΠ΅Π΄ΠΎΠ²Π°Π½Π½ΠΎΠΌΡ 5-Π°ΠΌΠΈΠ½ΠΎΠ»Π΅Π²ΡΠ»ΠΈΠ½ΠΎΠ²ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΠΎΠΉ (ΠΠΠ),
Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΡΡ
ΠΈ ΠΌΠ°Π»ΠΈΠ³Π½ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°. ΠΠ΅ΡΠΎΠ΄Ρ: ΠΎΠ±ΡΠ΅ΠΊΡΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ»ΡΠΆΠΈΠ»ΠΈ Π»ΠΈΠΌΡΠΎΡΠΈΡΡ, Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΠ΅
Ρ ΠΏΠΎΠΌΠΎΡΡΡ Π³ΡΠ°Π΄ΠΈΠ΅Π½ΡΠ° ΠΏΠ»ΠΎΡΠ½ΠΎΡΡΠΈ ΡΠΈΠΊΠΎΠ»Π»-Π²Π΅ΡΠΎΠ³ΡΠ°ΡΠΈΠ½Π° ΠΈΠ· ΠΊΡΠΎΠ²ΠΈ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π΄ΠΎΠ½ΠΎΡΠΎΠ² (6) ΠΈ Π³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
(20)
Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌΠΈ ΡΠΎΡΠΌΠ°ΠΌΠΈ Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎΠ·ΠΎΠ², Π° ΡΠ°ΠΊΠΆΠ΅ ΡΡΠ°Π½ΡΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π»ΠΈΠΌΡΠΎΡΠΈΡΡ Π-ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΡ
(Raji, Namalwa) ΠΈ Π’-ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΡ
(ΠΠ’-4, HUT-78) Π»ΠΈΠ½ΠΈΠΉ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°. ΠΠΈΠ°Π³Π½ΠΎΠ· Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»ΠΈΠΌΡΠΎΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΡΡΠ°Π²ΠΈΠ»ΠΈ Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ
ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ, ΡΠΈΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΡΠΈΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ ΠΈ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π°;
ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅Π½ΠΎΡΠΈΠΏΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΏΠ°Π½Π΅Π»ΠΈ ΠΌΠΎΠ½ΠΎΠΊΠ»ΠΎΠ½Π°Π»ΡΠ½ΡΡ
Π°Π½ΡΠΈΡΠ΅Π» ΠΊ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²ΠΎΡΠ½ΡΠΌ Π°Π½ΡΠΈΠ³Π΅Π½Π°ΠΌ
Π’-, Π-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ², NK-ΠΊΠ»Π΅ΡΠΎΠΊ ΠΈ ΠΠΠ‘-ΠΠ -ΠΌΠ΅ΡΠΎΠ΄Π°. Π’ΡΠ°Π½ΡΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π»ΠΈΠΌΡΠΎΡΠΈΡΡ ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΡ
Π»ΠΈΠ½ΠΈΠΉ ΠΊΡΠ»ΡΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π»ΠΈ Π²
ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎΠΉ RPMI-1640 ΡΡΠ΅Π΄Π΅ Ρ 10% ΡΠΌΠ±ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ ΡΠ΅Π»ΡΡΡΠ΅ΠΉ ΡΡΠ²ΠΎΡΠΎΡΠΊΠΎΠΉ. ΠΠ»Ρ ΡΠΎΡΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π²ΠΎΠ·Π΄Π΅ΠΉΡΡΠ²ΠΈΡ ΠΊΠ»Π΅ΡΠΊΠΈ
ΠΈΠ½ΠΊΡΠ±ΠΈΡΠΎΠ²Π°Π»ΠΈ Ρ 1,0β5,0 ΠΌΠ ΠΠΠ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 4 Ρ ΠΈ ΠΎΠ±Π»ΡΡΠ°Π»ΠΈ Π³Π΅Π»ΠΈΠΉ-Π½Π΅ΠΎΠ½ΠΎΠ²ΡΠΌ Π»Π°Π·Π΅ΡΠΎΠΌ (Π΄Π»ΠΈΠ½Π° Π²ΠΎΠ»Π½Ρ β 633 Π½ΠΌ), Π²Π°ΡΡΠΈΡΡΡ Π΄ΠΎΠ·Ρ ΠΎΡ
10 Π΄ΠΎ 150 ΠΠΆ/ΡΠΌ2
. ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΏΠΎΠ³ΠΈΠ±ΡΠΈΡ
ΠΊΠ»Π΅ΡΠΎΠΊ ΠΏΠΎΡΠ»Π΅ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ 20-ΡΠ°ΡΠΎΠ²ΠΎΠΉ ΠΈΠ½ΠΊΡΠ±Π°ΡΠΈΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠ΅ΡΡΠ°
Ρ ΡΡΠΈΠΏΠ°Π½ΠΎΠ²ΡΠΌ ΡΠΈΠ½ΠΈΠΌ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΡΠ΅ ΠΈ ΠΌΠ°Π»ΠΈΠ³Π½ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π»ΠΈΠΌΡΠΎΡΠΈΡΡ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° ΡΠ΅Π·ΠΊΠΎ ΠΎΡΠ»ΠΈΡΠ°ΡΡΡΡ ΠΏΠΎ
ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΊ ΠΠΠ-ΠΎΠΏΠΎΡΡΠ΅Π΄ΠΎΠ²Π°Π½Π½ΠΎΠΌΡ ΡΠΎΡΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΌΡ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ (ΠΠΠ-Π€Π). ΠΠ½Π°ΡΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΡΠ°ΡΡΡ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΠΊΡΠΎΠ²ΠΈ
Π±ΠΎΠ»ΡΠ½ΡΡ
Π»Π΅ΠΉΠΊΠΎΠ·ΠΎΠΌ (Π² ΡΡΠ΅Π΄Π½Π΅ΠΌ 62,06 Β± 4,03% Ρ 10 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π-ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎΠ·ΠΎΠΌ, Π-Π₯ΠΠ) ΠΏΠΎΠ³ΠΈΠ±Π°Π»Π°
ΠΏΡΠΈ ΠΌΠΈΠ½ΠΈΠΌΠ°Π»ΡΠ½ΡΡ
ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠ°Ρ
Π²ΠΎΠ·Π΄Π΅ΠΉΡΡΠ²ΠΈΡ (1 ΠΌΠ ΠΠΠ, Π΄ΠΎΠ·Π° ΠΎΠ±Π»ΡΡΠ΅Π½ΠΈΡ 25 ΠΠΆ/ΡΠΌ2
), ΡΠΎΠ³Π΄Π° ΠΊΠ°ΠΊ Π΄Π°ΠΆΠ΅ Π½Π°ΠΈΠ²ΡΡΡΠ°Ρ Π΄ΠΎΠ·Π° (5 ΠΌΠ
ΠΠΠ, 150 ΠΠΆ/ΡΠΌ2
) Π½Π΅ Π²Π»ΠΈΡΠ»Π° Π½Π° ΠΆΠΈΠ·Π½Π΅ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΡ Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΡΡ
Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ². Π ΠΎΠΏΡΡΠ°Ρ
in vitro Π² Π’-ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΡ
Π»ΠΈΠ½ΠΈΡΡ
ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΈ
Π±ΠΎΠ»ΡΡΠΈΠΉ ΠΏΡΠΎΡΠ΅Π½Ρ Π³ΠΈΠ±Π΅Π»ΠΈ ΠΊΠ»Π΅ΡΠΎΠΊ, ΡΠ΅ΠΌ Π² Π-ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΡ
. ΠΡΠΈ ΡΡΠΎΠΌ Π»ΠΈΠ½ΠΈΡ Raji ΠΎΡΠ»ΠΈΡΠ°Π΅ΡΡΡ ΠΏΠ°ΡΠ°Π΄ΠΎΠΊΡΠ°Π»ΡΠ½ΡΠΌ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ΠΌ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ
ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° ΠΏΠΎΠ³ΠΈΠ±ΡΠΈΡ
ΠΊΠ»Π΅ΡΠΎΠΊ ΠΎΡ Π΄ΠΎΠ·Ρ Π²ΠΎΠ·Π΄Π΅ΠΉΡΡΠ²ΠΈΡ, ΡΡΠΎ, ΠΏΠΎ-Π²ΠΈΠ΄ΠΈΠΌΠΎΠΌΡ, ΡΠ²ΡΠ·Π°Π½ΠΎ Ρ ΠΈΠ·Π²Π΅ΡΡΠ½ΡΠΌ Π΄Π»Ρ ΡΡΠΎΠΉ Π»ΠΈΠ½ΠΈΠΈ Π΄Π΅ΡΠ΅ΠΊΡΠΎΠΌ ΡΠΈΠ³Π½Π°Π»ΡΠ½ΡΡ
ΠΏΡΡΠ΅ΠΉ Π°ΠΏΠΎΠΏΡΠΎΠ·Π°. ΠΠ±ΡΡΠΆΠ΄Π°ΡΡΡΡ Π²Π΅ΡΠΎΡΡΠ½ΡΠ΅ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π½ΡΡ
ΠΎΡΠ»ΠΈΡΠΈΠΉ ΠΌΠ΅ΠΆΠ΄Ρ Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΡΠΌΠΈ ΠΈ ΠΌΠ°Π»ΠΈΠ³Π½ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌΠΈ
Π»ΠΈΠΌΡΠΎΡΠΈΡΠ°ΠΌΠΈ Π² ΠΊΠΎΠ½ΡΠ΅ΠΊΡΡΠ΅ Π°Π»ΡΡΠ΅ΡΠ°ΡΠΈΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠ² ΡΠΈΠ½ΡΠ΅Π·Π° ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ Π³Π΅ΠΌΠ° ΠΏΡΠΈ ΠΌΠ°Π»ΠΈΠ³Π½ΠΈΠ·Π°ΡΠΈΠΈ. ΠΡΠ²ΠΎΠ΄Ρ: 1) Π²ΠΏΠ΅ΡΠ²ΡΠ΅ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ,
ΡΡΠΎ ΠΌΠ°Π»ΠΈΠ³Π½ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π»ΠΈΠΌΡΠΎΡΠΈΡΡ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Π»ΠΈΠΌΡΠΎΠ»Π΅ΠΉΠΊΠΎΠ·ΠΎΠΌ ΠΏΡΠΎΡΠ²Π»ΡΡΡ Π²ΡΡΠΎΠΊΡΡ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΊ ΠΠΠ-Π€Π
ΠΏΡΠΈ ΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΎΡΡΡΡΡΡΠ²ΠΈΠΈ ΡΠ°ΠΊΠΎΠΉ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ Ρ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π΄ΠΎΠ½ΠΎΡΠΎΠ²; 2) ΠΎΠ·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π»Π΅Π½Π½ΡΠ΅ Π»ΠΈΠΌΡΠΎΡΠΈΡΡ
Π’-ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΡ
Π»ΠΈΠ½ΠΈΠΉ Π±ΠΎΠ»Π΅Π΅ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½Ρ ΠΊ ΠΠΠ-Π€Π ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ Π-ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌΠΈ; 3) Π΄Π»Ρ ΠΊΠ»Π΅ΡΠΎΠΊ Π»ΠΈΠ½ΠΈΠΈ Raji ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π°
Π°Π½ΠΎΠΌΠ°Π»ΡΠ½Π°Ρ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡ Π΄ΠΎΠ·Π°/ΡΡΡΠ΅ΠΊΡ; 4) Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ
ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½ ΠΏΡΠΎΡΡΠΎΠΉ ΠΈ ΠΌΠ°Π»ΠΎΡΡΠ°Π²ΠΌΠ°ΡΠΈΡΠ½ΡΠΉ ΡΠ΅ΡΡ
Π΄Π»Ρ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π° ΠΏΠΎΠΆΠΈΠ»ΡΡ
Π»ΡΠ΄Π΅ΠΉ Π½Π° Π½Π°Π»ΠΈΡΠΈΠ΅ Π-Π₯ΠΠ
Photodynamic activity of hematoporphyrin conjugates with gold nanoparticles: experiments in vitro
Aim: To synthesize a conjugate of hematoporphyrin with gold nanoparticles, and to evaluate its photodynamic activity in experiments on cultures of transformed cells. Methods: nanosized gold particles and nanocomposites synthesis methods, cell culture methods, photobiology methods, trypan blue dye exclusion test, chemiluminescence assay. Results: Various hematoporphyrin-gold nanocomposites were obtained, which contained similar hematoporphyrin concentration (5 ΞΌg/ml) and varied concentrations (0.5β5 ΞΌg/ml) of gold nanoparticles with a diameter of 15 nm or 45 nm. It was established by chemiluminescence method that nanocomposites synthesized induce more efficiently the formation of photo-oxidative products than original photosensitizer. The experiments with transformed cell lines showed that photodynamic in vitro activity of synthesized hematoporphyrin-nanogold composites is much higher than that of the original photosensitizer. The better activity of the nanocomposites with gold particles of 45 nm vs such of 15 nm which was demonstrated in the experiments, can be apparently connected with the fact that bigger particles are able to transport more porphyrin molecules into malignant cells. Conclusion: The results obtained warrant the necessity of further studies with hematoporphyrin-gold nanocomposites in vivo on transplanted tumors of animals which have to define the real perspectives of the nanocomposites application in PDT
Chronobiological approaches to antiangiogenic photodynamic therapy of tumors: the first experimental evaluatIon
In research of the last decade, rhythmic (circadian) variations of vascular endothelial growth factor (VEGF) production by tumors were discovered. The present paper authors have earlier synthesized and characterized a new derivative photosensitizer β an immunoconjugate of hematoporphyrin with antiVEGF antibodies. Aim: To elaborate and to test a novel modification of the photodynamic therapy of tumors (PDT) method, founding upon a timed introduction of the immunoconjugated photosensitizer to tumor-bearing animals, so that this coincides with a maximum content of VEGF in tumor tissues. Methods: Circadian variations of VEGF contents in murine transplanted tumors, Lewis lung carcinoma and sarcoma 180, were determined by ELISA method. Immunoconjugated photosensitizer concentrations in tumors were estimated by spectrofluorometry. Photoirradiation of the tumors was carried out with a red light (wavelength of 635 nm) from a semiconductor laser. Light doses were chosen, calculating on a partial inhibition of tumor growth, in order that a dependence of PDT efficiency on a daily time-moment (circadian rhythm phase) of the treatment could be observed distinctly. Results: Circadian variations of the VEGF levels in Lewis lung carcinoma and sarcoma 180 were demonstrated with the maximum at 14:00 h and the minimum at 02:00 h. Intra-abdominal introduction into tumor-bearing mice of the immunoconjugated photosensitizer resulted in a greater accumulation of the immunoconjugate in tumors at 14:00 h than at 02:00 h. Laser irradiation of carcinomas and sarcomas at 14:00 h or 02:00 h after introduction of the immunoconjugated photosensitizer to mice the day before at the same time points, induced a significantly enhanced inhibition of tumor growth in animals treated at day-time versus those treated at night-time. Conclusion: The obtained results justify further attempts to transfer principles of tumor chronochemotherapy onto photodynamic therapy
Circadian rhythms of cytotoxic activity in peripheral blood mononuclear cells of patients with malignant melanoma
Aim: To study circadian rhythms (CR) of cytotoxic activity in peripheral blood mononuclear cells of patients with malignant melanoma were compared with those in healthy men. Methods: The NK-cell and phagocyte cytotoxic activity in five patients with malignant melanoma stage I or II and 12 healthy donors has been assessed by radioimmune assay and NBT-test. Results: The circadian rhythmicity in NK-cells and phagocyte activity in all cancer patients under study has been disrupted. The extent of such disruption tended to increase in patients with more advanced cancer. The most typical alterations were discoordination between the cytotoxicity rhythms of NK-cells and phagocytes (synchronized in healthy persons) and alterations in basic rhythm parameters: phase shifts and amplitude damping. Conclusion: In melanoma patients the significant alteration of CR in NK-cells and phagocytes cytotoxic activity was revealed. In spite of individual variations, the degree of the rhythm disruption basically depended on a disease stage. The alteration of CR phase and amplitude and discoordination between the rhythms of NK- cells and phagocyte were registered in all cases studied.Π¦Π΅Π»Ρ: ΠΈΠ·ΡΡΠΈΡΡ ΡΠΈΡΠΊΠ°Π΄ΠΈΠ°Π½Π½ΡΠ΅ ΡΠΈΡΠΌΡ (Π¦Π ) ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΌΠΎΠ½ΠΎΠ½ΡΠΊΠ»Π΅Π°ΡΠ½ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΡΠΎ-
Π²ΠΈ (ΠΠΠΠ) Π±ΠΎΠ»ΡΠ½ΡΡ
Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΌΠ΅Π»Π°Π½ΠΎΠΌΠΎΠΉ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΡΠ°ΠΊΠΎΠ²ΡΠΌΠΈ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π΄ΠΎΠ½ΠΎΡΠΎΠ². ΠΠ΅ΡΠΎΠ΄Ρ: Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ
ΠΠ-ΠΊΠ»Π΅ΡΠΎΠΊ ΠΈ ΠΠΠΠ, Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΡΡ
ΠΈΠ· ΠΊΡΠΎΠ²ΠΈ 5 Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠΎ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΌΠ΅Π»Π°Π½ΠΎΠΌΠΎΠΉ I ΠΈ II ΡΡΠ°Π΄ΠΈΠΉ ΠΈ 12 Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π΄ΠΎΠ½ΠΎΡΠΎΠ²,
ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΡΠΈ ΠΏΠΎΠΌΠΎΡΠΈ ΡΠ°Π΄ΠΈΠΎΠΈΠΌΠΌΡΠ½Π½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π° ΠΈ NBT-ΡΠ΅ΡΡΠ°. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Ρ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
Π½Π°ΡΡΡΠ΅Π½Π° Π½ΠΎΡΠΌΠ°Π»ΡΠ½Π°Ρ ΡΠΈΡΠΊΠ°Π΄ΠΈΠ°Π½Π½Π°Ρ ΡΠΈΡΠΌΠΈΡΠ½ΠΎΡΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΠ-ΠΊΠ»Π΅ΡΠΎΠΊ ΠΈ ΠΠΠΠ, ΠΏΡΠΈΡΠ΅ΠΌ ΡΡΠ΅ΠΏΠ΅Π½Ρ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΡΠ°ΠΊΠΈΡ
Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡΠ°Π΅Ρ ΠΏΠ°ΡΠ°Π»Π»Π΅Π»ΡΠ½ΠΎ Ρ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΠ΅ΠΉ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. Π Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠΈΠΏΠΈΡΠ½ΡΠΌ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡΠΌ ΠΎΡΠ½ΠΎΡΡΡΡΡ Π΄ΠΈΡΠΊΠΎΠΎΡΠ΄ΠΈ-
Π½Π°ΡΠΈΡ ΠΌΠ΅ΠΆΠ΄Ρ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΡΠΈΡΠΌΠ°ΠΌΠΈ ΠΠ-ΠΊΠ»Π΅ΡΠΎΠΊ ΠΈ ΠΌΠΎΠ½ΠΎΠ½ΡΠΊΠ»Π΅Π°ΡΠ½ΡΠΌΠΈ ΡΠ°Π³ΠΎΡΠΈΡΠ°ΠΌΠΈ (ΡΠΈΠ½Ρ
ΡΠΎΠ½ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌΠΈ Ρ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π΄ΠΎΠ½ΠΎΡΠΎΠ²) ΠΈ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΎΡΠ½ΠΎΠ²Π½ΡΡ
ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ² ΡΠΈΡΠΌΠ°: ΡΠ΄Π²ΠΈΠ³ ΡΠ°Π· ΠΈ ΡΠΌΠ΅ΡΠ΅Π½ΠΈΡ Π°ΠΌΠΏΠ»ΠΈΡΡΠ΄Ρ. ΠΡΠ²ΠΎΠ΄Ρ: Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΌΠ΅Π»Π°Π½ΠΎΠΌΠΎΠΉ Π²ΡΡΠ²-
Π»Π΅Π½Ρ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ Π¦Π ΠΠ-ΠΊΠ»Π΅ΡΠΎΠΊ ΠΈ ΠΠΠΠ, ΠΏΡΠΈΡΠ΅ΠΌ ΡΡΠ΅ΠΏΠ΅Π½Ρ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΡΠΈΡΠΌΠ° Π·Π°Π²ΠΈΡΠΈΡ ΠΎΡ ΡΡΠ°Π΄ΠΈΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ.
ΠΠΎ Π²ΡΠ΅Ρ
ΠΈΠ·ΡΡΠ΅Π½Π½ΡΡ
ΡΠ»ΡΡΠ°ΡΡ
Π²ΡΡΠ²Π»Π΅Π½Ρ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΠ°Π· ΠΈ Π°ΠΌΠΏΠ»ΠΈΡΡΠ΄Ρ Π¦Π , Π΄Π΅ΠΊΠΎΠΎΡΠ΄ΠΈΠ½Π°ΡΠΈΡ ΡΠΈΡΠΌΠΎΠ² ΠΠ-ΠΊΠ»Π΅ΡΠΎΠΊ ΠΈ ΠΠΠΠ.
ΠΠ»ΡΡΠ΅Π²ΡΠ΅ ΡΠ»ΠΎΠ²Π°: Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½Π°Ρ ΠΌΠ΅Π»Π°Π½ΠΎΠΌΠ°, ΡΠΈΡΠΊΠ°Π΄ΠΈΠ°Π½Π½ΡΠΉ ΡΠΈΡΠΌ, Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΠ-ΠΊΠ»Π΅ΡΠΎΠΊ, ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ
ΠΌΠΎΠ½ΠΎΠ½ΡΠΊΠ»Π΅Π°ΡΠ½ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ
Hyperflav β perspective photosensitizer for PDT: cell studies
Present studies investigated the effectiveness in vitro of Hyperflav application as a photosensitizer for photodynamic therapy
Photodynamic responsiveness of human leukemia Jurkat/A4 cells with multidrug resistant phenotype
Photodynamic therapy (PDT) is considered as a possible alternative approach to overcoming multidrug resistance (MDR). Analysis of cross-resistance to PDT in cells with different MDR pathways and resistance levels seems to be advantageous for elucidating the general mechanisms of cancer cell resistance to various treatment modalities. Aim: The aim of the study was to clarify whether the Jurkat/A4 leukemia cells with MDR phenotype are cross-resistant to PDT. Methods: Human T-cell acute lymphoblastic leukemia line Jurkat and Jurkat/A4 subline with MDR phenotype were used. 5-Aminolevulinic acid (ALA) and Photolon (a complex of chlorine-e6 and polyvinylpyrrolidone; PL) or gold nanocomposite of PL were applied as photosensitizers. The cells were pretreated with photosensitizers and exposed to laser radiation at corresponding wavelengths. The phototoxicity was assessed in trypan blue exclusion test. The hypodiploid cell fraction was analyzed by flow cytometry of propidium iodide-stained cells. Expression of genes related to PDT resistance was analyzed by microarray technique with Affymetrix U133A chips. Results: ALA-mediated PDT resulted in dose-dependent cell death in both lines, the relative photodynamic efficacy in Jurkat/A4 cells being inferior to that in the parental Jurkat cells. There was no correlation between phototoxicity and apoptosis induction both in Jurkat and Jurkat/A4 cells. PL-mediated general phototoxicity in Jurkat cells amounted up to 75% at the maximal photosensitizer dose with about 40% of apoptotic death fraction. PL-phototoxicity in Jurkat/A4 cells was considerably lower. In contrast to Jurkat cells, PL-gold composite did not increase the efficacy of photosensitization as compared to free PL in Jurkat/A4 cells. Conclusions: Multidrug-resistant Jurkat/A4 cells exhibit reduced sensitivity to phototoxic effect in comparison with parental Jurkat cells independently of nature of the photosensitizer being assayed. Key Words: photodynamic therapy, leukemia cells, multidrug resistance, apoptosis
Water soluble, multifunctional antibody-porphyrin gold nanoparticles for targeted photodynamic therapy
Photodynamic therapy (PDT) is a treatment of cancer by which tumour cells are destroyed using reactive oxygen species produced by photosensitizers following activation with visible or near infrared light. Successful PDT depends on the solubility and the targeting ability of the photosensitizers. In this work, the synthesis of a porphyrin-based water soluble nanoparticle conjugate containing a targeting agent that recognizes the erbB2 receptor overexpressed on the surface of particular cancer cells is reported. The nanoparticle conjugates were synthesized following two different protocols, viz. a biphasic and a monophasic method, with the aim to determine which method yielded the optimal nanosystem for potential PDT applications. The nanoparticles were characterized using UVβVis absorption and fluorescence spectroscopies together with transmission electron microscopy and zeta potential measurements; and their ability to produce singlet oxygen following irradiation was investigated following the decay in absorption of a singlet oxygen probe. The nanoparticles synthesized using the monophasic method were shown to produce the highest amount of singlet oxygen and were further functionalized with anti-erbB2 antibody to target the erbB2 receptors expressed on the surface of SK-BR-3 human breast cancer cells. The water soluble, antibody-porphyrin nanoparticle conjugates were shown to elicit targeted PDT of the breast cancer cells
Photosensitiser-gold nanoparticle conjugates for photodynamic therapy of cancer
Gold nanoparticles (AuNPs) have been extensively studied within biomedicine due to their biocompatibil- ity and low toxicity. In particular, AuNPs have been widely used to deliver photosensitiser agents for photodynamic therapy (PDT) of cancer. Here we review the state-of-the-art for the functionalisation of the gold nanoparticle surface with both photosensitisers and targeting ligands for the active targeting of cancer cell surface receptors. From the initial use of the AuNPs as a simple carrier of the photosensitiser for PDT, the field has significantly advanced to include: the use of PEGylated modification to provide aqueous compatibility and stealth properties for in vivo use; gold metal-surface enhanced singlet oxygen generation; functionalisation of the AuNP surface with biological ligands to specifically target over- expressed receptors on the surface of cancer cells and; the creation of nanorods and nanostars to enable combined PDT and photothermal therapies. These versatile AuNPs have significantly enhanced the efficacy of traditional photosensitisers for both in vitro and in vivo cancer therapy. From this review it is apparent that AuNPs have an important future in the treatment of cancer
- β¦